Significance of circulatory DPP4 activity in metabolic diseases
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Dipeptidyl peptidase 4 (DPP4), also known as CD26 is a type II transmembrane protein that is released from the cell membrane in a nonclassical secretory mechanism. This exopeptidase selectively degrades varieties of substrates including incretin hormones, growth factors, and cytokines. A significant detectable amount of DPP4 activity can be measured in plasma as well as in different tissues such as intestinal epithelium, vascular endothelium, lymphocytes, monocytes, kidney, liver, adipose, lung, thymus, spleen, prostate, etc. Enzymatically active circulatory DPP4 is shed from the plasma membrane via proteolytic cleavage, a process responsible for the enhanced plasma DPP4 levels and activity. Elevated circulatory DPP4 activity as well as levels has been found in wide spectrum of metabolic diseases including diabetes, obesity, cardiovascular diseases, and nonalcoholic fatty liver diseases. Moreover, recent preclinical studies have further expanded the repertoire for the usage of DPP4 inhibitors in the treatment of other metabolic diseases and in their consequent complications. In the present review we highlight the reason behind the elevated circulatory DPP4 levels in metabolic diseases with a focus on the tissue of origin. We also underscore the discrepancy of protein levels with enzyme activity of circulatory DPP4 in metabolic diseases. © 2018 IUBMB Life, 70(2):112–119, 2018
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation, stress, and diabetes
Wellen, K. E., & Hotamisligil, G. S. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25102 · Cited by 4,143
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“DPP4 inhibitors (sitagliptin, saxagliptin, and vildagliptin) thus prolong the insulinotropic effect of incretins are now in clinical use as antidiabetic drugs (8,9).”
BackgroundThe biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Lambeir, A.-M., Durinx, C., Scharpé, S., & De Meester, I. (2003) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/713609354 · Cited by 955
Shirakawa, J., Fujii, H., Ohnuma, K., Sato, K., Ito, Y., Kaji, M., Sakamoto, E., Koganei, M., Sasaki, H., Nagashima, Y., et al. (2011) · Diabetes · doi:10.2337/db10-1338 · Cited by 246
Finding New Treatments for Diabetes — How Many, How Fast . . . How Good?
Nathan, D. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmp068294 · Cited by 216 · cited 1×
“DPP4 inhibitors (sitagliptin, saxagliptin, and vildagliptin) thus prolong the insulinotropic effect of incretins are now in clinical use as antidiabetic drugs (8,9).”
BackgroundLiu, L., Liu, J., Wong, W. T., Tian, X. Y., Lau, C. W., Wang, Y.-X., Xu, G., Pu, Y., Zhu, Z., Xu, A., et al. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.195115 · Cited by 179 · cited 1×
“In several in vivo and pre-preclinical studies, DPP4 inhibitor have been shown to protect endothelium from hypertension (49), improve myocardial function, and protect cardiomyocytes from ischemic damage (50).”
BackgroundDobrian, A. D., Ma, Q., Lindsay, J. W., Leone, K. A., Ma, K., Coben, J., Galkina, E. V., & Nadler, J. L. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00463.2010 · Cited by 166 · cited 1×
“Moreover, DPP4 inhibitor drug sitagliptin has an antiinflammatory property (42,43) which reduces inflammatory gene expressions such as TNF-a, TLR-4, TLR-2, JNK-1, IKKb, and CCR2 in peripheral blood mononuclear cells (43).”
BackgroundOhki, T., Isogawa, A., Iwamoto, M., Ohsugi, M., Yoshida, H., Toda, N., Tagawa, K., Omata, M., & Koike, K. (2012) · The Scientific World Journal · doi:10.1100/2012/496453 · Cited by 139 · cited 1×
“Secretion of DPP4 from different cells in different metabolic diseases: DPP4 is shredded from (1) T lymphocytes in patients with T2DM via KLK5, (2) endothelial cells in cardiovascular disease, (3) adipocytes in obesity via MMPs, (4) smooth muscle in healthy individual via MMPs, and (5) hepatocytes in NAFLD patients.”
BackgroundDipeptidyl peptidase IV (DDP IV) in NASH patients
Balaban, Y. H., Korkusuz, P., Simsek, H., Gokcan, H., Gedikoglu, G., Pinar, A., Hascelik, G., Asan, E., Hamaloglu, E., & Tatar, G. (2007) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31905-2 · Cited by 125
Mulvihill, E. E., Varin, E. M., Gladanac, B., Campbell, J. E., Ussher, J. R., Baggio, L. L., Yusta, B., Ayala, J., Burmeister, M. A., Matthews, D., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2016.10.007 · Cited by 102 · cited 4×
“In high-fat diet fed mice gut selective endothelial DPP4 inhibition by sitagliptin improves oral glucose tolerance test and is responsible for 50% inactivation of incretin hormone such as GLP-1 (48) that directly stimulates insulin secretion in response to meal.”
BackgroundInfluential
Cited by
Trends in insulin resistance: insights into mechanisms and therapeutic strategy
Li, M., Chi, X., Wang, Y., Setrerrahmane, S., Xie, W., & Xu, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01073-0 · Cited by 939
Yu, Y., Zhang, M., Li, J., Liu, Z., Lyu, L., Xiao, Y., Yang, G., Liu, J., Wang, Q., Ding, X., et al. (2025) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.5c00025 · Cited by 12
Fecal Dipeptidyl Peptidase-4: An Emergent Biomarker in Inflammatory Bowel Disease
Pinto-Lopes, P., Melo, F., Afonso, J., Pinto-Lopes, R., Rocha, C., Melo, D., Macedo, G., Dias, C. C., Carneiro, F., Magro, F., et al. (2021) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000320 · Cited by 11
Metadata
- Authors
- Nargis, T., & Chakrabarti, P.
- Venue
- IUBMB Life
- Publisher
- Wiley
- Published
- 2018-01-13
- Volume
- 70
- Issue
- 2
- Pages
- 112-119
- ISSN
- 1521-6543 (ISSN-L)
- 1521-6551
- OpenAlex
- W2783691705
- Cited by
- 80
- References
- 11
- FWCI
- 2.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.